AN2 Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
AN2 Therapeutics, Inc. (ANTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.01 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-11
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 1.01M shares, a 2.03% decline year-over-year.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 1.22M shares, a 28.49% decline from fiscal 2024.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.70M shares, a 38.86% increase from fiscal 2023.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.22M shares, a 1.13% decline from fiscal 2022.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.24M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 1.01M shares 10-Q · filed 2026-08-11 | 1.01M shares derived: sum of 3 quarters · filed 2026-08-11 | 1.01M shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 1.01M shares 10-Q · filed 2026-05-11 | 1.01M shares derived: sum of 2 quarters · filed 2026-05-11 | 1.01M shares derived: sum of 3 quarters · filed 2026-05-11 | 1.20M shares derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-17 | 187.39K shares derived: sum of 3 quarters · filed 2026-03-17 | 1.22M shares 10-K · filed 2026-03-17 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 187.39K shares derived: sum of 2 quarters · filed 2025-11-12 | 1.22M shares 10-Q · filed 2025-11-12 | 1.45M shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 187.39K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 1.22M shares 10-Q · filed 2025-08-12 | 1.45M shares derived: sum of 3 quarters · filed 2025-08-12 | 1.45M shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 1.03M shares 10-Q · filed 2025-05-13 | 1.26M shares derived: sum of 2 quarters · filed 2025-05-13 | 1.26M shares derived: sum of 3 quarters · filed 2025-05-13 | 1.80M shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 229.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | 229.70K shares derived: sum of 2 quarters · filed 2025-03-25 | 769.42K shares derived: sum of 3 quarters · filed 2025-03-25 | 1.70M shares 10-K · filed 2025-03-25 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 539.72K shares derived: sum of 2 quarters · filed 2024-11-13 | 1.47M shares 10-Q · filed 2024-11-13 | 1.60M shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 539.72K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 1.47M shares 10-Q · filed 2024-08-13 | 1.60M shares derived: sum of 3 quarters · filed 2024-08-13 | 1.60M shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 931.48K shares 10-Q · filed 2024-05-14 | 1.06M shares derived: sum of 2 quarters · filed 2024-05-14 | 1.06M shares derived: sum of 3 quarters · filed 2024-05-14 | 1.23M shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 131.04K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | 131.04K shares derived: sum of 2 quarters · filed 2024-03-29 | 302.93K shares derived: sum of 3 quarters · filed 2024-03-29 | 1.22M shares 10-K · filed 2024-03-29 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 171.89K shares derived: sum of 2 quarters · filed 2023-11-09 | 1.09M shares 10-Q · filed 2023-11-09 | 1.42M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 171.89K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 1.09M shares 10-Q · filed 2023-08-10 | 1.42M shares derived: sum of 3 quarters · filed 2023-08-10 | 1.42M shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 922.00K shares 10-Q · filed 2023-05-11 | 1.25M shares derived: sum of 2 quarters · filed 2023-05-11 | 1.25M shares derived: sum of 3 quarters · filed 2023-05-11 | 2.09M shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 327.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | 327.75K shares derived: sum of 2 quarters · filed 2023-03-29 | 1.16M shares derived: sum of 3 quarters · filed 2023-03-29 | 1.24M shares 10-K · filed 2023-03-29 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 836.97K shares derived: sum of 2 quarters · filed 2022-11-09 | 911.20K shares 10-Q · filed 2022-11-09 | |
| 2022-06-30 | 836.97K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 911.20K shares 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | 74.23K shares 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |